Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV single-arm study of Sanfeng Tongqiao Dropping Pills for acute rhinitis
ChiCTR2200057768Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sanfeng Tongqiao Diwan in nasopharyngitis, sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Disease response rate after 4 days of administration. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
Sanfeng Tongqiao Diwan
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ChiCTR2200057768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057768.